IPP Bureau
Bristol Myers Squibb to provide Eliquis free to Medicaid
By IPP Bureau - December 21, 2025
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
Merck strikes historic deal with Trump admin to lower drug costs for Americans
By IPP Bureau - December 21, 2025
Takeda posts strong Phase 3 win for oral psoriasis drug
By IPP Bureau - December 21, 2025
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease
By IPP Bureau - December 21, 2025
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Qihan Biotech launches first-in-human trial of off-the-shelf CAR-T therapy for refractory lupus
By IPP Bureau - December 21, 2025
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease
By IPP Bureau - December 20, 2025
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
Briefs: APL Healthcare, Biocon, USFDA, Sun Pharma and Clean Fino-Chem
By IPP Bureau - December 20, 2025
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity
By IPP Bureau - December 20, 2025
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year
By IPP Bureau - December 20, 2025
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery
By IPP Bureau - December 20, 2025
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Pfizer and Cipla forge exclusive marketing and distribution pact for key brands in India
By IPP Bureau - December 20, 2025
This marks the first partnership between Pfizer and Cipla in India
Fortis invests Rs. 840 crore for 300+ beds in Bengaluru
By IPP Bureau - December 20, 2025
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%
By IPP Bureau - December 20, 2025
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Lupin signs exclusive licensing pact with Neopharmed for Plasil in Philippines and Brazil
By IPP Bureau - December 19, 2025
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
